
|Articles|April 1, 2019
- Pharmaceutical Executive-04-01-2019
- Volume 39
- Issue 4
Pharmaceutical Executive, April 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Biosimilars Name Game Remains Thorny Issueover 6 years ago
HBA's Woman of the Year 2019over 6 years ago
Sharing Your Voiceover 6 years ago
Health Technology’s Double-Edged Swordover 6 years ago
True Grit: Talent Management from the Ground Upover 6 years ago
Reinventing Pharma’s Talent Searchover 6 years ago
Hiring a Chief Diversity Officerover 6 years ago
Are Pharma Marketers Fighting the Last War?over 6 years ago
Ready Patient Oneover 6 years ago
Country Report: ChinaNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
2
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
3
Alnylam Announces $250 Million Investment in Massachusetts Facility
4
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
5




